tirzepatide from china to usa With approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs Eli Lilly Partners With China

Patients often report noticeable improvements in pain and function within the first 1-2 weeks for acute injuries, though tissue remodeling continues for months

Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate

For thyroid patients facing stubborn weight, this extra effectiveness matters

Using Wegovy consistently helps ensure the drug works effectively

Lifting Techniques: When lifting objects, bend your knees and keep your back straight

Treatments based on GLP-1 have the potential to play an important role in addressing this growing public health concern